Crispr Therapeutics AG Surges on Takeover Buzz and Hype

Crispr Therapeutics AG ( (CRSP) ) has risen by 11.41%. Read on to learn why.

Crispr Therapeutics AG shares have climbed 11.41% over the past week as renewed takeover speculation and upbeat analyst sentiment drew fresh investor interest. A Betaville M&A blog post highlighting new chatter about a potential acquisition of the gene-editing specialist revived rumors first floated in late 2025, sparking heavier trading and a “Buy” technical signal in a stock that has otherwise been volatile, with year-to-date gains of 5.26% and a modest market cap of around $5.45 billion.

Beyond deal rumors, fundamentals and Wall Street views have helped underpin the move. Citi’s Yigal Nochomovitz reaffirmed a Buy rating and lifted his price target to $80, citing much stronger-than-expected sales of Casgevy, Crispr’s flagship gene-editing therapy, aided by a broad global rollout, solid U.S. reimbursement and faster uptake. He also pointed to a busy 2026 pipeline, from cardiovascular and siRNA programs to the zugo‑cel autoimmune and oncology efforts, which together could unlock multiple value-creating data readouts.

Other analysts echoed that optimism: Piper Sandler reiterated a Buy with a $105 target, while Chardan Capital maintained a Buy with a $76 target. Consensus on Wall Street sits at a Moderate Buy with an average price target of about $73, implying meaningful upside from recent levels despite a 7.43% decline over the past six months. For investors, the combination of takeover chatter, accelerating commercial traction for Casgevy and a catalyst-rich pipeline has made Crispr Therapeutics AG one of the more closely watched healthcare names in the market this week.